Acorda Therapeutics Shares Outstanding 2006-2021 | ACOR

Acorda Therapeutics shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Acorda Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 8
2019 8
2018 8
2017 8
2016 8
2015 7
2014 7
2013 7
2012 7
2011 7
2010 6
2009 6
2008 6
2007 4
2006 3
2005 0
Acorda Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 10
2021-03-31 9
2020-12-31 8
2020-09-30 28
2020-06-30 8
2020-03-31 8
2019-12-31 8
2019-09-30 8
2019-06-30 8
2019-03-31 8
2018-12-31 8
2018-09-30 8
2018-06-30 8
2018-03-31 8
2017-12-31 8
2017-09-30 8
2017-06-30 8
2017-03-31 8
2016-12-31 8
2016-09-30 8
2016-06-30 8
2016-03-31 7
2015-12-31 7
2015-09-30 7
2015-06-30 7
2015-03-31 7
2014-12-31 7
2014-09-30 7
2014-06-30 7
2014-03-31 7
2013-12-31 7
2013-09-30 7
2013-06-30 7
2013-03-31 7
2012-12-31 7
2012-09-30 7
2012-06-30 7
2012-03-31 7
2011-12-31 7
2011-09-30 7
2011-06-30 6
2011-03-31 6
2010-12-31 6
2010-09-30 7
2010-06-30 6
2010-03-31 6
2009-12-31 6
2009-09-30 6
2009-06-30 6
2009-03-31 6
2008-12-31 6
2008-09-30 6
2008-06-30 5
2008-03-31 5
2007-12-31 4
2007-09-30 5
2007-06-30 4
2007-03-31 4
2006-12-31 3
2006-09-30 3
2006-06-30 3
2006-03-31 2
2005-12-31 0
2005-09-30 0
2005-06-30 0
2005-03-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.053B $0.153B
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29